← Leaderboards
John S Chorba
University Of California, San Francisco
$6,529,968
Attributed
$6,677,908
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2012–24$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,677,908 · 8
By mechanism
R01$4,250,384 · 2
K08$878,090 · 1
R61$537,538 · 1
R21$444,125 · 1
R43$295,881 · 1
R03$160,377 · 1
Top collaborators
- John Maidens1 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Priscilla Y. Hsue$28,957,856
- Adam Rao$147,607
- Devan Jaganath$2,782,826
- Melinda Diver$980,821
Others in their field
Top investigators on “Atherosclerosis”
- Eric A Boerwinkle · University Of Texas Hlth Sci Ctr Houston$63,519,256
- Josef Coresh · New York University School Of Medicine$60,445,875
- Daniel James Rader · University Of Pennsylvania$50,278,074
- Howard N Hodis · University Of Southern California$49,943,399
- Gary K Owens · University Of Virginia$42,472,259
- Alan Richard Tall · Columbia University Health Sciences$38,866,887
Research focus
AtherosclerosisMediatingLow-Density LipoproteinsLow Density Lipoprotein ReceptorPharmaceutical PreparationsCellsSmall MoleculeEventBlood CirculationCholesterolCardiovascular SystemDrug TargetingClinicPeptide HydrolasesCell SurfaceRegulationMolecular ChaperonesBindingTherapeutic TargetInsightAffectInnovationIn VitroBiological
Grant awards (24)
CSDE1 as a Post Transcriptional Regulator of the LDLR$621,179
R01 · FY2024 · HL · contact PI
Chemical Biology to Modulate PCSK9 and Treat Atherosclerosis$363,375
R01 · FY2024 · HL · contact PI
CSDE1 as a Post Transcriptional Regulator of the LDLR$630,223
R01 · FY2023 · HL · contact PI
Small molecule allosteric inhibitors of PCSK9 processing to phenocopy cardioprotective genetic variants.$537,538
R61 · FY2023 · HL · contact PI
Chemical Biology to Modulate PCSK9 and Treat Atherosclerosis$363,375
R01 · FY2023 · HL · contact PI
Chemical Biology to Modulate PCSK9 and Treat Atherosclerosis$93,412
R01 · FY2023 · HL · contact PI
CSDE1 as a Post Transcriptional Regulator of the LDLR$626,993
R01 · FY2022 · HL · contact PI
Chemical Biology to Modulate PCSK9 and Treat Atherosclerosis$363,375
R01 · FY2022 · HL · contact PI
Sequence Specific Inhibition of Protein Translation$201,875
R21 · FY2022 · GM · contact PI
CSDE1 as a Post Transcriptional Regulator of the LDLR - Diversity Supplement$97,076
R01 · FY2022 · HL · contact PI
Chemical Biology to Modulate PCSK9 and Treat Atherosclerosis$93,412
R01 · FY2022 · HL · contact PI
CSDE1 as a Post Transcriptional Regulator of the LDLR$634,589
R01 · FY2021 · HL · contact PI
Chemical Biology to Modulate PCSK9 and Treat Atherosclerosis$363,375
R01 · FY2021 · HL · contact PI
Sequence Specific Inhibition of Protein Translation$242,250
R21 · FY2021 · GM · contact PI
Probing the multiple roles of the PCSK9 active site using chemical biology$187,760
K08 · FY2019 · HL · contact PI
Mediators of PCSK9 Secretion as Targets Against Atherosclerosis$80,335
R03 · FY2019 · HL · contact PI
Deep Learning for Automated Aortic Stenosis and Valvular Heart Disease Detection Using a Digital Stethoscope$295,881
R43 · FY2018 · HL
Probing the multiple roles of the PCSK9 active site using chemical biology$184,960
K08 · FY2018 · HL · contact PI
Mediators of PCSK9 Secretion as Targets Against Atherosclerosis$80,042
R03 · FY2018 · HL · contact PI
Probing the multiple roles of the PCSK9 active site using chemical biology$183,040
K08 · FY2017 · HL · contact PI
Probing the multiple roles of the PCSK9 active site using chemical biology$181,280
K08 · FY2016 · HL · contact PI
Probing the multiple roles of the PCSK9 active site using chemical biology$141,050
K08 · FY2015 · HL · contact PI
Targeting the serine protease PCSK9 via covalent complementarity$53,779
F32 · FY2013 · HL · contact PI
Targeting the serine protease PCSK9 via covalent complementarity$57,734
F32 · FY2012 · HL · contact PI